Synopsis: Wockhardt Ltd shares rally 37% in the last two days after FDA approval of ZAYNICH™ for cUTI, which showed 89% cure vs 68.4% with meropenem in Phase 3 ENHANCE-1, with QIDP/Fast Track status and global filings underway. The shares of a Mid-Cap company...
Synopsis: Healthcare stock surged 12 percent after FY26 results, driven by strong biotech growth, emerging market expansion, margin improvement, and a turnaround in profitability to Rs 199 crore PAT. The share of this company, which focuses on pharmaceutical...
The shares of the pharmaceutical company specializing in the pharmaceutical and biotechnology sectors, focusing on the research, development, manufacturing, and marketing, are in focus as the stock has rallied upto 19 percent in the day’s trade. In this article, let’s...
During Monday’s trading session, the shares of a research-based Global Pharmaceutical and Biotech company surged nearly 4 percent to Rs. 1,441.95, after its antibiotic drug ‘Zaynich’ achieved 97 percent effectiveness in treating severe pneumonia infections. With...
